HDR Prostate Brachytherapy.

Area of Science:

• Oncology
• Radiation Oncology
• Urologic Oncology

Background:

• Brachytherapy is a cornerstone in treating localized prostate cancer.
• Dose escalation in brachytherapy correlates with improved patient outcomes.
• High-dose-rate brachytherapy (HDR-BT) has evolved for efficient administration in 1-2 fractions.

Purpose of the Study:

• To review the development and evolution of HDR-BT for prostate cancer.
• To outline patient selection criteria and treatment outcomes for HDR-BT.
• To provide a detailed description of HDR-BT techniques in prostate cancer management.

Main Methods:

• Review of historical development and technological advancements in HDR-BT.
• Analysis of clinical data regarding patient selection and treatment results.
• Detailed explanation of procedural techniques for HDR-BT delivery.

Main Results:

• HDR-BT, as monotherapy or combined with external beam radiation, provides significant advantages.
• Precise dose delivery enables focal dose escalation and organ sparing, maintaining excellent tolerance.
• The high dose per fraction leverages the prostate cancer's low α/β ratio, enhancing radiation sensitivity.

Conclusions:

• HDR-BT is an established and effective treatment modality for localized prostate cancer.
• Technological advancements and precise delivery allow for tailored dose escalation and toxicity management.
• Further understanding of HDR-BT mechanisms may optimize treatment strategies and patient outcomes.